GW Pharma denies supply issues with cannabis-based drug Epidiolex after stock falls

Hemp Industry Daily
By Nick ThomasFeb 21, 2019, 2:15 pm348 pts
GW Pharmaceuticals, the British maker of epileptic seizure-control medication Epidiolex, said it was not aware of any supply issues related to the cannabis-derived drug after a tweet from a patient’s father complained he could not source the medicine. GW’s stock was down more than 3% on Wednesday on the…

Read Article Share
Share Article
- email
- twitter
- facebook
- pocket
- reddit
- tumblr
- linkedin
- pinterest

Trending Today on NewsBudz

Golden Bear Awards: California’s 2025 Best Cannabis Flower, Products Announced 76

USDA Database Describes Marijuana As ‘Medicinal’ Even As Federal Government Keeps It In Schedule I 76

Three Ways to Spice Up Your Summer Sesh 72

Last call at the hemp THC beverage bar in St. Louis? 72

Florida marijuana patients can lose access under new state law 70

How to Be Your Own Cannabis Sommelier 67

'The Studio' Racks Up 23 Emmy Nom for Seth Rogen, Bryan Cranston, Zoë Kravitz, Dave Franco and More 66

Nebraska: Omaha Tribe Approves Marijuana Legalization on Reservation Lands 66

About NewsBudz

NewsBudz is your go-to app for daily cannabis news, covering everything from medical marijuana breakthroughs to recreational cannabis trends and legalization updates.

Our platform aggregates content from over 30 top-tier cannabis news outlets to deliver a curated stream of the latest headlines, insights, and developments across the marijuana and hemp industries.

Whether you're interested in policy reform, health research, cannabis business, CBD, delta 9 products or lifestyle stories, NewsBudz keeps you informed and connected. Accessible on the web and mobile, NewsBudz makes it easy to explore, read, and share cannabis news anytime, anywhere.